Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood|September 10, 2005
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphomaMartin Hutchings, Annika Loft, Mads Hansen, et al.
International Journal of Cancer|February 14, 2008
Hepatitis C infection and risk of malignant lymphomaClaudia Schöllkopf, Karin Ekström Smedby, Henrik Hjalgrim, et al.
Journal of the National Cancer Institute|February 3, 2005
Ultraviolet radiation exposure and risk of malignant lymphomasKarin Ekström Smedby, Henrik Hjalgrim, Mads Melbye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962Philip M P Poortmans, Hanneke C Kluin-Nelemans, Hanny Haaxma-Reiche, et al.
The Lancet. Oncology|April 11, 2008
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) studyMichael Pfreundschuh, Anthony D Ho, Eva Cavallin-Stahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2007
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish studyAndrea Gallamini, Martin Hutchings, Luigi Rigacci, et al.
The Lancet. Oncology|May 2, 2006
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupMichael Pfreundschuh, Lorenz Trümper, Anders Osterborg, et al.
Pageof 3